Claret Bioscience and New England Biolabs (NEB® ) have entered into a co-promotion agreement to support researchers using SRSLY® MethylPlus in combination with the NEBNext® EM-seq™ v2 Conversion Module.
SRSLY MethylPlus and SRSLY Uracil+ products are designed to integrate with enzymatic methyl-conversion workflows, enabling high-quality library preparation for methylation profiling and fragmentomics research. The collaboration with NEB provides researchers with a validated workflow option that combines SRSLY MethylPlus library construction with EM-seq v2 conversion chemistry.
This combined workflow supports research with:
Whole-genome methylation analysis
Targeted methylation studies
cfDNA Fragmentomics research
Broader epigenomic applications
SRSLY-based workflows are designed for compatibility with diverse methyl-conversion workflows, enabling researchers to select configurations best suited to their applications. The SRSLY MethylPlus workflow works with inputs as low as 100pg to 50ng for downstream methyl-conversion.
The NEBNext® EM-seq™ v2 Conversion Module is an enzyme-based method for the identification of 5mC and 5hmC from as little as 100 picograms of input DNA. According to Teni Dowdell, Corporate and Business Development Manager at New England Biolabs, “We’re excited for this partnership to demonstrate the capabilities of Enzymatic Methyl-seq in conjunction with SRSLY single-stranded library preparation”
For additional technical information or workflow guidance, please contact our teams.
About ClaretBio
Claret Bioscience develops cutting-edge nucleic acid library preparation kits tailored for fragmented and degraded samples. Their patented SRSLY® technology enables ultra-efficient single-stranded DNA and RNA library prep, optimized for applications ranging from cfDNA to ancient DNA and FFPE-derived material. ClaretBio manufactures the kits under ISO13485 certified manufacturing facilities in Scotts Valley, California.
SRSLY® and SRSLY® MethylPlus are registered trademarks of Claret Bioscience LLC.
About New England Biolabs
For over 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers' research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 11 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit www.neb.com.
NEW ENGLAND BIOLABS®, NEB®, and NEBNEXT® are registered trademarks of New England Biolabs, Inc.